Corporate News
Keros Therapeutics (ticker: KROS) advanced by 3.07 % in the 24‑hour trading window that closed at 07:22 PM Central Europe on Wednesday, 21 March 2027. At the time of reporting, the share price stood at approximately USD 11.19 on the most liquid exchanges. The company’s outstanding share count is 19.8 million, which, together with the current market price, yields a market capitalization of about USD 219.3 million. In the preceding 24 hours, roughly USD 1.7 million worth of shares changed hands, equating to a modest volume relative to the firm’s liquidity.
The 200‑day simple moving average sits at USD 12.36, while the all‑time high reached USD 22.55 on 12 August 2025, and the 52‑week low was USD 9.69 on 4 August 2026. Compared with the close at the end of last month, the share price has slipped 0.7 %.
Recent Corporate Developments
Keros Therapeutics has announced that it expects a development milestone payment of USD 20 million from Takeda following the first‑patient dosing in its Phase III trial of elritercept for patients with myelofibrosis and anemia. This milestone mirrors a comparable payment received in an earlier myelodysplastic syndromes study and is projected to be distributed with 25 % allocated to shareholders. The company’s cash reserves stand at approximately USD 257 million as of June 2026, which is sufficient to fund operations through the first half of 2028.
No additional regulatory or partnership updates were disclosed at the time of this report. The modest price increase observed in the most recent session reflects the market’s positive reaction to the milestone announcement and the company’s solid liquidity position.
Comparative Performance of Related Stocks
| Ticker | Recent Change | Current Price (USD) | Market Cap (USD mn) | P/E Ratio |
|---|---|---|---|---|
| TRGS (Latin America Cl) | –0.1 % | 9.96 | 259.4 | – |
| HWBK (Hawthorn Bancshares) | +1.52 % | 38.18 | 263.1 | 10.38 |
| NCZ‑PA (Virtus Convertible & Income) | –0.25 % | 18.10 | 262.8 | 3.63 |
| SES (Ses Ai) | –9.57 % | 0.59 | 259.9 | – |
| RWAY (Runway Growth Finance) | +0.32 % | 6.33 | 261.5 | 32.59 |
Note: The price‑to‑earnings ratios are provided where available. Negative or missing values indicate that the metric was not disclosed or not applicable at the time of reporting.
Contextual Update on Ses Ai
Ses Ai announced a new development in its satellite operations following the launch of Planet’s Pelican‑12. The high‑resolution satellite, equipped with advanced imaging and edge‑computing capabilities, will support data‑relay experiments involving Ses Ai’s O3b mPOWER network. The collaboration highlights the company’s strategy to integrate satellite‑to‑satellite communications and reduce data‑delivery latency for commercial users, thereby expanding its service portfolio in real‑time geospatial intelligence.
Company Profile
Keros Therapeutics, Inc. is a biotechnology enterprise headquartered in Lexington, United States, specializing in the discovery and development of innovative therapies for hematological and musculoskeletal disorders that exhibit high unmet medical need. The company operates globally, serving patients worldwide and maintaining a focus on translating scientific breakthroughs into clinically meaningful treatments.